Diabetes Mellitus, Type II
Conditions
Keywords
Glucokinase agonist, HM-002-1005, Hyperglycemia, Diabetes Mellitus, Type II, Single dose escalation
Brief summary
The purposes of this study are to: * Evaluate the safety and tolerability of the study drug. * Measure how much of the study drug (HM-002-1005) and its breakdown product get into the bloodstream, and how long it takes the body to get rid of them. * Measure the amount of glucose (blood sugar) and a substance called C-peptide in the bloodstream after receiving the study drug. Researchers will compare the study drug to a placebo (a look-alike substance that contains no drug). Participants will: * Stay 5 days and 4 nights or 6 days and 5 nights at the research site, and have a follow-up phone call 7 days after leaving the research site. * Take one (1) dose of the study drug or placebo * Have blood taken to measure the amount of study drug and its breakdown product and the levels of glucose and C-peptide * Have safety tests such as vital sign, ECGs, and glucose measurements
Interventions
DRUGHM-002-1005
HM-002-1005 extended release tablets for oral administration compared with matching placebo tablets
Sponsors
Hua Medicine Limited
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
matching placebo control
Intervention model description
single oral dose escalation study
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Males or females, of any race, between 18 and 65 years of age, inclusive. 2. Body mass index between 18.5 and 38.0 kg/m2, inclusive. 3. Females will not be pregnant or lactating, and females of childbearing potential and males will agree to use contraception. 4. Type 2 diabetes mellitus, as determined by the American Diabetes Association (ADA) Standard Care Diagnostic Criteria 2023, and 1. are drug naïve, treated with diet and exercise, or 2. have been on a stable dose of ≤2000 mg metformin for ≥1 month, or 3. have been on a stable dose of antidiabetic medications (other than metformin) for ≥90 days. 5. Except for findings consistent with T2DM, in good health, determined from medical history, 12 lead electrocardiogram (ECG), vital signs measurements, clinical laboratory evaluations, and physical examinations at screening and/or check in, as assessed by the investigator (or designee). 6. Glycated hemoglobin between 6.5% and 9.5%, inclusive. 7. Fasting plasma glucose between 126 and 196 mg/dL (7 and 11 mmol/L, respectively), inclusive. Testing may be repeated once, at the discretion of the investigator (or designee). Other Inclusions 8. Able to comprehend and willing to sign an ICF and to abide by the study restrictions.
Exclusion criteria
1. Type 1 diabetes mellitus, maturity onset diabetes of the young, or diabetes mellitus caused by damage to the pancreas or any other condition (eg, acromegaly or Cushing's syndrome). 2. Diabetic neuropathy, retinopathy, or nephropathy. 3. Acute or chronic metabolic acidosis, including diabetic ketoacidosis. 4. History of severe hypoglycemia, defined as severe cognitive impairment requiring external assistance for recovery within 3 months prior to dosing; or recurrent hypoglycemia (Level 2), defined as ≥2 episodes within 3 months prior to dosing; or ADA Level 3 hypoglycemia within 6 months prior to dosing. 5. Hypoglycemia unawareness or asymptomatic hypoglycemia. 6. Clinically significant history of liver disease (eg, hepatitis and cirrhosis) within 1 year prior to screening. 7. Clinically significant history of renal disease. Mild to moderate chronic kidney disease is permitted. 8. Clinically significant history of cardiovascular disease, particularly coronary artery disease, arrhythmias, atrial tachycardia, or congestive heart disease within 1 year prior to screening. Managed hypertension is permitted. 9. Clinically significant history of any central nervous system disease, including transient ischemic attack, stroke, seizure disorder, depression, or behavioral disturbances within 1 year prior to screening. 10. Clinically significant gastric emptying abnormality (eg, severe diabetic gastroparesis or gastric outlet obstruction) or have had gastric bypass surgery. 11. Clinically significant or unstable history of any hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, endocrine, or psychiatric disorder, as determined by the investigator (or designee). 12. Known or active malignancy, except basal cell carcinoma and cutaneous squamous cell carcinoma. 13. Any hospital admission or major surgery within 90 days prior to screening. 14. History of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, as determined by the investigator (or designee). 15. Fasting C peptide \<0.81 ng/mL. 16. Alanine aminotransferase, aspartate aminotransferase, or gamma glutamyl transferase \>2 × the upper limit of normal (ULN); or total bilirubin \>1.5× ULN. 17. Uncontrolled hypertriglyceridemia \>500 mg/dL. 18. Estimated glomerular filtration rate ≤45 mL/min/1.73 m2, as calculated using the 2021 Chronic Kidney Disease Epidemiology equation. 19. QT interval corrected for heart rate using Fridericia's method \>450 msec. 20. Positive hepatitis panel and/or positive human immunodeficiency virus test . 21. Positive pregnancy test. 22. Use of insulin, sulfonylureas, and glinides (eg, repaglinide and nateglinide). 23. Use of any strong or moderate cytochrome P450 (CYP) 3A4 inducers within 28 days prior to dosing or any strong or moderate CYP3A4 inhibitors within 7 days or 5 half lives, whichever is longer, prior to dosing. 24. Use of any P glycoprotein inducers within 14 days prior to dosing or any P glycoprotein inhibitors within 5 days or 5 half lives, whichever is longer, prior to dosing 25. Use of any carboxylesterase 2 inhibitors within 5 days or 5 half lives, whichever is longer, prior to dosing Note: The use of hypertensive therapies is permitted, providing that they are do not meet
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events | 11 Days | incidence and severity of adverse events from Day1 to Day 11 |
| Area under the plasma concentration versus time curve (AUC) | 72 hour | area under the concentration-time curve from time 0 to 72 hours postdose of HM-002-1005 in plasma |
| maximum observed concentration (Cmax) | 72 hours | Cmax of HM-002-1005 in plasma |
| time of the maximum observed concentration (Tmax) | 72 hours | Tmax of HM-002-1005 in plasma |
| apparent terminal elimination half life (t1/2) | 72 hours | t1/2 of HM-002-1005 in plasma |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| glucose concentration following single oral dose of HM-002-1005 | 24 hours | serum glucose concentration over 24 hours after dosing |
Countries
United States
Outcome results
None listed